Rapid Wane and Recovery of XBB Sublineage Neutralization After Sequential Omicron-based Vaccination in Solid Organ Transplant Recipients.

Autor:	Johnston TS; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Hage C; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Abedon AT; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Panda S; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Alejo JL; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Eby Y; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Segev DL; Department of Surgery, NYU Grossman School of Medicine, New York, New York, USA., Tobian AAR; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Cox AL; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.; W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.; Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Werbel WA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Karaba AH; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Jazyk:	angličtina
Zdroj:	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2024 Sep 26; Vol. 79 (3), pp. 652-655.
DOI:	10.1093/cid/ciae279
Abstrakt:	Durability of variant neutralization in solid organ transplant recipients following Omicron-containing boosters is unknown. We report wane in XBB.1.5 neutralization by 3 months following a first bivalent booster, improved by a second booster; hybrid immunity improved peak, and duration of neutralization. Boosting at 3 to 6 months appears necessary to maintain neutralization. Competing Interests: Potential conflicts of interest. D. L. S. reports receiving consulting and/or speaking honoraria from Sanofi, Novartis, Veloxis, Mallinckrodt, Jazz Pharmaceuticals, CSL Behring, Thermo Fisher Scientific, Caredx, Transmedics, Kamada, MediGO, Regeneron, AstraZeneca, Takeda/Shire, Novavax, and Bridge to Life. W. A. W. has received consulting and/or speaking fees from AstraZeneca, GlobalData, China Medical Tribune, Medical Learning Institute (CME), and advisory board fees from AstraZeneca and Novavax. A. H. K. has received consulting fees from Hologic Inc. and speaking fees from PRIME Education (CME). All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu